Happy new year!
Everyone at the Swiss NASH Foundation wishes you a happy and healthy new year 2024!
Glucagon-like peptide-1 receptor agonists and risk of major adverse liver outcomes in patients with chronic liver disease and type 2 diabetes | Gut
Barcelona is walking the walk and getting in their steps today! A great way to experience Barcelona following a fantastic NIT Summit and SLD Think-Tank the last 2 days. Congratulations to @JVLazarus Lazarus and @schattenbergJ, the amazing faculty and all the participants that…
#GUTImages from the paper by @AngeloArmandi et al on
"Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease" via https://bit.ly/49y90Dd
@DinaTiniakos @lucavalenti75 @lmiele74 @hanneshagstrom @mromerogomez
RT @MadrigalPharma: #BREAKING It is a big day for the Liver Community! Madrigal is proud to announce the first and only @US_FDA-approved th…